1. Show article details.

    AbbVie urges U.S. court to avoid gay rights issue in HIV drug case

    Reuters – 3:46 PM ET 04/18/2014

    An Abbott Laboratories (ABT) spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc (GSK), but without disturbing landmark constitutional protections for gays and lesbians.

  2. Show article details.

    RPT-UPDATE 2-Abbott beats profit forecast, but sales lag

    Reuters – 10:51 AM ET 04/16/2014

    Abbott Laboratories Inc reported better-than-expected quarterly earnings on cost controls, but sales came in slightly below Wall Street expectations. The company on Wednesday said it earned $375 million, or 24 cents per share in the first quarter. Excluding special charges, Abbott earned 41 cents per share.

  3. Show article details.

    Abbott Labs Profit Falls 31%

    DJ Business News – 8:44 AM ET 04/16/2014

    Abbott Laboratories (ABT) said its first-quarter earnings fell 31% as the health-care products company reported negative currency impact that masked modest overall sales growth. Abbott has faced continuing challenges stemming from a recall last year by one of its baby-formula suppliers, Fonterra Co-Operative Group Ltd. The recall led Abbott and competitor Danone SA to take their own products off the market across Asia. The scare was prompted by a Fonterra warning that its...

  4. Show article details.

    Abbott Laboratories beats profit forecast, sales lags

    Reuters – 8:26 AM ET 04/16/2014

    Abbott Laboratories Inc reported better-than-expected earnings in the first quarter on Wednesday, but sales came in slightly below Wall Street expectations. The company said it earned $375 million, or 24 cents per share in the three months ended March 31. Excluding special charges, Abbott earned 41 cents per share.

  5. Show article details.

    Abbott Laboratories profit beats forecast, but sales lag

    Reuters – 8:09 AM ET 04/16/2014

    Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday, but combined sales of its nutritional products, medical devices and generic medicines were slightly below Wall Street expectations. The company earned $375 million, or 24 cents a share, in the three months ended March 31. Excluding special charges, Abbott earned 41 cents per share.

  6. Show article details.

    Abbott Reports First-Quarter 2014 Results

    PR Newswire – 7:45 AM ET 04/16/2014

    ABBOTT PARK, Ill., April 16, 2014 Abbott (ABT) today announced financial results for the first quarter ended March 31, 2014. "We are off to a good start, and we continue to expect accelerating performance beginning in the second quarter as we target another year of double-digit ongoing earnings-per-share growth," said Miles D. White, chairman and chief executive officer, Abbott.

  7. Show article details.

    RBCC Bioprinting Partner Expands Brand Awareness Campaign

    Business Wire – 4:28 AM ET 04/16/2014

    Rainbow Coral Corp.’s (RBCC) 3D bioprinting partner, Nano3D Biosciences, has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.

  8. Show article details.

    Abbott Laboratories Statement re Current Reports

    DJ Business News – 2:15 AM ET 04/16/2014

    Headline: Abbott Laboratories Files Forms 8- K. Abbott Laboratories Files Forms 8- K. The Company informs its shareholders that on 24 February 2014 and 28 March 2014, in accordance with the U.S.

  9. Show article details.

    Abbott Laboratories Statement re Proxy Materials

    DJ Business News – 2:15 AM ET 04/16/2014

    Headline: Abbott Laboratories Files Proxy Materials. Abbott Laboratories Files Proxy Materials. The Company informs its shareholders that on 14 April 2014 and 14 March 2014, in accordance with the U.S.

  10. Show article details.

    Abbott Announces FDA Clearance for a New Test to Help Physicians Quickly and Accurately Diagnose Diabetes

    PR Newswire – 9:00 AM ET 04/14/2014

    ABBOTT PARK, Ill., April 14, 2014 Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has received 510 clearance from the U.S. Food and Drug Administration.

  11. Show article details.

    Google, Intel, IBM outlooks to trump earnings results

    MarketWatch – 8:31 AM ET 04/13/2014

    SAN FRANCISCO-- For stocks to stem their recent bleeding, outlooks from heavy-hitters such as Google Inc., Intel Corp. (INTC) and International Business Machines Corp. (IBM) will need to show the economy is rebounding after a weather- stilted first quarter. Company forecasts for the second quarter will likely carry more weight than actual first-quarter earnings results this season. Most investors have already accepted that first-quarter earnings results will be unimpressive due to...

  12. Show article details.

    MARKET SNAPSHOT: Google, Intel, IBM Outlooks To Trump Earnings Results

    DJ Business News – 8:31 AM ET 04/13/2014

    SAN FRANCISCO-- For stocks to stem their recent bleeding, outlooks from heavy-hitters such as Google Inc., Intel Corp. (INTC) and International Business Machines Corp. (IBM) will need to show the economy is rebounding after a weather- stilted first quarter. Company forecasts for the second quarter will likely carry more weight than actual first-quarter earnings results this season. Most investors have already accepted that first-quarter earnings results will be unimpressive due to...

  13. Show article details.

    Healthcare Companies Enter into Acquisitions and Partnerships, Receive FDA Approvals, Make Appointments, and Receive Recognitions - Analyst Notes on Nordion, Abbott, Covidien, DaVita, and Sirona

    PR Newswire – 8:00 AM ET 04/11/2014

    NEW YORK, April 11, 2014 Today, Analysts Review released its analysts' notes regarding Nordion Inc. (NDZ), Abbott Laboratories (ABT), Covidien plc (COV), DaVita HealthCare Partners Inc. (DVA), and Sirona Dental Systems Inc. (SIRO). Private wealth members receive these notes ahead of publication.

  14. Show article details.

    Abbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China

    PR Newswire – 8:30 AM ET 04/10/2014

    ABBOTT PARK, Ill., April 10, 2014Abbott today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market.

  15. Show article details.

    Financial Release Schedule -- Research on Abbott Laboratories, PNC, American Express, and Plexus

    PR Newswire – 10:58 AM ET 04/09/2014

    LONDON, April 9, 2014 Earnings Source provides investors with earnings schedule updates throughout the earnings season. SOURCE Earnings Source.

  16. Show article details.

    RBCC and n3D Seek Out Additional Capital

    Business Wire – 5:00 AM ET 04/09/2014

    Rainbow Coral Corp. (RBCC) and its joint venture partner, Nano3D Biosciences are seeking out new finance partners to market and develop their 3D bioprinting technology worldwide. The joint venture is working to raise approximately $1-3 million to further market and develop the BiO Assay product line.

  17. Show article details.

    Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution

    Business Wire – 5:00 AM ET 04/03/2014

    By substantially increasing its investment in biotech innovators Nano3D Biosciences, Rainbow Coral Corp. (RBCC) has positioned itself on the front lines of a bioprinting revolution poised to forever alter the possibilities of healthcare.

  18. Show article details.

    Health Care Stocks on our Radar -- Research on Abbott Laboratories, Medtronic, Hologic, and ArthroCare

    PR Newswire – 10:59 AM ET 04/02/2014

    LONDON, April 2, 2014 On Tuesday, April 1, 2014, the NASDAQ Composite ended at 4,268.04, up 1.64%, the Dow Jones Industrial Average advanced 0.46% to finish at 16,532.61, and the S&P 500 closed at 1,885.52, up 0.70%. The gains were broad based with eight out of ten sectors finishing the session in positive. SOURCE Investor-Edge.

  19. Show article details.

    Trial Results, Product Approvals, Upcoming Meetings, Dividend Announcements, and Product Comparisons - Analyst Notes on Amgen, Abbott, Express Scripts, Zoetis, and Edwards

    PR Newswire – 8:00 AM ET 04/02/2014

    NEW YORK, April 2, 2014 Today, Analysts Review released its analysts' notes regarding Amgen Inc. (AMGN), Abbott Laboratories (ABT), Express Scripts Holding Company (ESRX), Zoetis Inc. (ZTS), and Edwards Lifesciences Corp. (EW). Private wealth members receive these notes ahead of publication.

  20. Show article details.

    Abbott Hosts Conference Call for First-Quarter Earnings

    PR Newswire – 9:00 AM ET 04/01/2014

    ABBOTT PARK, Ill., April 1, 2014Abbott will announce its first-quarter 2014 financial results on Wednesday, April 16, 2014, before the market opens.

Page:

Today's and Upcoming Events

  • Apr
    25

    Shareholders Meeting

  • Jul
    16

    ABT to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Apr
    16

    ABT Earnings Conference Call at 9:00 AM Listen

  • Apr
    16

    ABT to announce Q1 earnings

    • Next earnings date: 7/16/2014
  • Apr
    11

    ABT ex-Dividend for $0.22 on 4/11/2014

    • Announce Date: 2/21/2014
    • Record Date: 4/15/2014
    • Pay Date: 5/15/2014
Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.